Abstract
Idiopathic membranous nephropathy is a common cause of nephrotic syndrome in adult population and can lead to CKD if not treated properly. Conventional therapeutic options like Cyclophosphamide & CNI associated with significant toxicity & relapse rate. Though Rituximab is relatively safe multiple dose protocol leads to high cost burden. In this trial single dose Rituximab therapy has been compared with multiple dose regimen for this which will significantly cut down cost and drug related adverse effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
